glp 1 how is it made The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity The GLP-1 journey: from discovery

If you experience any unexpected symptoms whilst participating in a trial, you should: Contact your trial coordinator immediately, as trial participants must report adverse events through their study team Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk if appropriate Seek urgent medical attention if symptoms are severe Current Availability and Regulatory Status in the UK Neither cagrilintide nor retatrutide holds MHRA marketing authorisation in the UK

doi:10.3390/ijms20174092 14

doi: 10.1016/S0168-9452(97)00262-8 289 VecchiB.AnM

As heavy metals are mobilized from tissue storage sites into the bloodstream for excretion, some patients may experience a temporary exacerbation of symptoms, such as mild fatigue, headaches, or gastrointestinal changes